Madrigal Pharmaceuticals, Inc. — Q3 2021 Form 10-Q
Business context and period. Clinical-stage biopharmaceutical company developing resmetirom (MGL-3196), primarily for NASH. The report covers the quarter and nine months ended September 30, 2021. The company had no product revenue and remained focused on Phase 3 development.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $54.9m | $53.3m | $152.3m | $131.4m |
| General and administrative expense | $8.3m | $5.5m | $25.6m | $15.7m |
| Net loss | $63.1m | $58.0m | $177.3m | $143.1m |
| Basic and diluted loss per share | $3.79 | $3.75 | $10.84 | $9.27 |
| Net cash used in operating activities | — | — | $135.9m | $102.6m |
Margins are not meaningful because the company reported no revenue. At September 30, 2021, cash and cash equivalents were $49.2m and marketable securities were $250.0m, totaling $299.1m, versus $284.1m at December 31, 2020. Total assets were $304.7m and stockholders’ equity was $234.9m. Total liabilities were $69.8m, primarily current operating accruals and lease liabilities; the filing reports no borrowings or other material debt. Current assets were $303.0m and current liabilities $69.3m.
Material changes versus comparable periods
- Q3 net loss increased $5.1m, or 9%, year over year; nine-month net loss increased $34.2m, or 24%.
- Nine-month R&D expense rose $20.9m, or 16%, mainly from Phase 3 trial activity, headcount and stock compensation. G&A increased $9.9m, or 63%, largely due to commercial preparation, added headcount and stock compensation.
- Nine-month interest income declined to $0.3m from $3.9m, mainly because of lower interest rates.
- Operating cash use increased to $135.9m from $102.6m. Financing provided $151.7m, principally from ATM stock sales; the company reported a net $151.2m in equity-issuance proceeds.
Outlook, risks and notable items
- Management expects losses and substantial R&D spending to continue and anticipates R&D and G&A expenses may increase as trials advance and commercial preparation expands. It believes available cash and investments at September 30, 2021 would fund operations for more than one year from issuance of the financial statements; longer-term funding needs may require further financing.
- MAESTRO-NASH and MAESTRO-NAFLD-1 Phase 3 studies were ongoing. The company reported reaching the enrollment required to support its planned Subpart H filing in MAESTRO-NASH in June 2021; this is not an approval or a guarantee of trial outcomes. The filing provides no specific financial guidance or confirmed future trial-readout dates.
- Risks include clinical-trial enrollment, safety and results; regulatory approval; commercialization and reimbursement; competition; and the availability and terms of future financing. The company said COVID-19 had no material adverse impact on results, MAESTRO-NAFLD-1 or liquidity through the period, but continued to pose operational and trial uncertainties.
- After quarter-end through November 2, 2021, the company sold 236,879 additional shares under its ATM agreement for approximately $19.0m net proceeds. Approximately $159.2m remained available under the agreement after those sales. Equity financing creates dilution risk.
- Potential Roche milestones totaled $8m, tied to future regulatory approvals, with single-digit royalties on resmetirom product sales. There were no product sales or new milestones reported. No material pending legal proceedings were disclosed.
Key facts for investors to verify
- Progress, enrollment, timing, safety and endpoint results for the resmetirom Phase 3 program, and the status and requirements of any planned FDA submission.
- Cash burn and runway assumptions against increasing trial and commercial-preparation costs; the filing’s runway estimate is management’s assessment, not a guarantee.
- Future ATM usage, remaining offering capacity, share dilution and any additional financing needs.
- Any changes to the $8m Roche milestone obligations, royalty terms, or other material commitments.